US03828A1016 - Common Stock
NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA...
Coupang stock is rallying on Wednesday as investors in CPNG celebrate the company beating out EPS and revenue estimates for Q4.
Applied Therapeutics stock is rising higher on Wednesday alongside heavy trading of APLT following an update from the FDA.
Applied Therapeutics (APLT) saw a significant boost in pre-market trade, with shares rising 51.5% after announcing plans to raise $100M through a private...
Financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with...
PDUFA target action date of August 28, 2024 MAA validated and accepted for review by EMA in December 2023 NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) --...
Applied Therapeutics (APLT) sotck rises as its late-stage trial for lead asset govorestat hits main goals in Sorbitol Dehydrogenase ((SORD)) Deficiency. Read more here.
Intellia Therapeutics layoffs are in the news on Friday as the biotech company prepares to cut its total workforce by 15% to reduce costs.
Safe and Green Development stock is up on Friday as investors in SGD celebrate the company's plans to acquire Majestic World Holdings.
Applied Therapeutics stock is tumbling on Friday as investors react to lackluster results from a Phase 3 clinical trial of AT-001.
Applied Therapeutics APLT -29% on mixed results from a Phase 3 study of its drug AT-001, which showed no significant difference in improvement or stabilization of cardiac functional capacity
Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!
Applied Therapeutics (APLT) stock plunged 30% in post-market trading Thursday after the biotech company reported mixed results from a Phase 3 study of its drug
AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months AT-001...
Applied Therapeutics stock surges 10% as the company submits applications for FDA and EU approval for its drug govorestat in galactosemia treatment.